Immunogenicity and Safety Study of a Third Vaccination With FSME-IMMUN 0.5 mL in Subjects Previously Vaccinated According to a Rapid Immunization Schedule (Follow-up to Study 225)
Open-Label, Follow-up, Phase IV Clinical Study to Evaluate the Immunogenicity and Safety of a Third Vaccination With FSME-IMMUN 0.5 mL in Subjects Previously Vaccinated Using a Rapid Immunization Schedule (Follow-up to Study 225)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Antwerp, Belgium, 2060
- SGS Biopharma Research Unit Stuivenberg
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female subjects who:
- received 2 vaccinations with FSME-IMMUN 0.5 ml during Study 225
- understand the nature of the study, agree to its provisions and provide written informed consent
- are clinically healthy (i.e. the physician would have no reservation vaccinating with FSME-IMMUN 0.5 ml outside the scope of the clinical trial)
- have a negative pregnancy test result at the first medical examination (if female and capable of bearing children)
- agree to employ adequate birth control measures for the duration of the study (if female and capable of bearing children)
- agree to keep a Subject Diary
Exclusion Criteria:
Subjects who:
- have already been administered a third TBE vaccination elsewhere since receiving two vaccinations in Study 225
- have a history of infection with, or vaccination against, other flaviviruses since participation in Study 225 (e.g. yellow fever, dengue fever, japanese B encephalitis)
- have had an allergic reaction to one of the components of the vaccine since participation in Study 225
- suffer from a disease (e.g. autoimmune disease, immunodeficiency) or are undergoing a form of treatment (e.g., systemic corticosteroids) that can be expected to influence immunological functions
- have a known or suspected problem with drug or alcohol abuse (>4 liters wine/week or equivalent doses of other alcoholic beverages)
- have donated blood or plasma within 30 days of study entry
- have received a blood transfusion or immunoglobulins within 30 days of study entry
- are known to be HIV positive (an HIV test is not required specifically for this study)
- are simultaneously participating in another clinical trial including administration of an investigational product
- have participated in any other clinical study within 6 weeks prior to study start
- have participated in another Baxter vaccine study in the past 6 months (with the exception of follow-up studies)
- For female subjects: pregnancy or lactation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Baxter BioScience Investigator, MD, Baxter BioScience
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Study Completion
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Encephalitis, Arbovirus
- Encephalitis, Viral
- Central Nervous System Viral Diseases
- Central Nervous System Infections
- Infectious Encephalitis
- Arbovirus Infections
- Vector Borne Diseases
- Flavivirus Infections
- Flaviviridae Infections
- Tick-Borne Diseases
- Encephalitis
- Encephalitis, Tick-Borne
- Anti-Infective Agents
- Disinfectants
- Formaldehyde
Other Study ID Numbers
Other Study ID Numbers
- 690501
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.